Using natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer

(E-pub Ahead of Print)

Author(s): Mahruba Sultana Niloy, Md. Salman Shakil, Md. Meharab Hassan Alif, Rhonda J. Rosengren*

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer
Call for Editor


Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant-based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and down-stream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

Keywords: KRAS, NSCLC, phytochemicals, cell signaling, cell cycle, and apoptosis

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 28 February, 2021
(E-pub Ahead of Print)
DOI: 10.2174/0929867328666210301105856
Price: $95

Article Metrics

PDF: 154